Ghent (Belgium), September 18th, 2018 - The Belgian life sciences venture fund V-Bio Ventures (www.v-bio.ventures) today announces that it joins the “Series B” financing round of Horama (www.horama.fr). Horama is a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare genetic diseases in ophthalmology.  Willem Broekaert, Managing Partner at V-Bio Ventures, will be appointed to the Horama Board.

Hot on the tail of Galapagos' successful public offering, Gent-based biotech Argenx is following suit! The biotech company, which is developing antibody-based therapies for cancer and autoimmune diseases, is offering $300 millions ADSs. This is the same amount offered by Galapagos, just last week. Belgian biotech is on a roll! All we can ask is; who's next?

Janssen Pharmaceutica have signed a renewal of the innovation charter with Ghent University (UGent) and Ghent University Hospital (UZ Gent). The move is part of an initiative to share more knowledge and expertise between industry and academia, stimulating scientific progress and reaching patients faster than ever before.

Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new methods for screening libraries of small molecules for the discovery of new therapeutic candidates targeting G-protein coupled receptors (GPCRs), using the company’s proprietary conformation-sensitive single domain antibodies or Confobodies.